Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avacta Group plc ( (GB:AVCT) ) just unveiled an announcement.
Avacta Group’s therapeutics division has unveiled new data showing its pre|CISION-based candidate FAP-Exd (AVA6103) could deliver cancer drugs more selectively and effectively than Enhertu, a leading antibody drug conjugate. Using an AI-generated synthetic comparator to replicate published AstraZeneca data, the company compared payload delivery in FAP-high animal models across two similar exatecan-family payloads.
The analysis suggests AVA6103 achieves faster tumor penetration, a more than tenfold higher peak drug concentration in tumor tissue, and a nearly threefold higher tumor selectivity index versus Enhertu’s T-Dxd, underpinning deeper and more durable responses in preclinical models. Avacta plans to start a Phase 1 clinical trial of AVA6103 in the first quarter of 2026 and will present the findings at upcoming scientific forums, potentially strengthening its position in the competitive oncology drug delivery space and raising expectations among investors and partners for the platform’s clinical performance.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £48.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on GB:AVCT Stock
According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on GB:AVCT stock, click here.
More about Avacta Group plc
Avacta Therapeutics, a division of Avacta Group plc, is a clinical-stage biopharmaceutical company focused on expanding the reach of highly potent cancer therapies. Its core pre|CISION platform uses a fibroblast activation protein–targeted peptide system to deliver cytotoxic payloads selectively to solid tumors while reducing exposure and toxicity in healthy tissue.
The company’s pipeline includes pre|CISION peptide drug conjugates and Affimer drug conjugates, which aim to offer advantages over traditional antibody drug conjugates. By harnessing tumor-specific protease activity to trigger local drug release, Avacta seeks to optimise dosing, improve tolerability and enhance clinical outcomes across a range of oncology indications.
Average Trading Volume: 2,252,436
Technical Sentiment Signal: Sell
Current Market Cap: £236.2M
See more data about AVCT stock on TipRanks’ Stock Analysis page.